Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Colon Clinical Trial

Official title:
An Eight-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome

Status Completed

Clinical Trial Summary

This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00101985
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	October 2004
Completion date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01855711` - Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)	Phase 2
Terminated	`NCT00423345` - Colon Investigation - Factors Determining Choice of Procedure
Completed	`NCT00376896` - Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers	Phase 1
Completed	`NCT00067561` - Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy	Phase 3
Completed	`NCT00067457` - Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy	Phase 3
Terminated	`NCT00461682` - Sb-705498 Rectal Pain Study	Phase 2
Completed	`NCT00385099` - Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome	Phase 2
Completed	`NCT00370032` - Study to Assess the Effect Of Alosetron On Mucosal Blood Flow	Phase 4